How US FDA's Assumptions Impacted Generic Program Fees

FDA decided against trying to predict upcoming approvals as part of FY 2019 GDUFA program fee calculations, but other adjustments likely increased fee significantly.

FDAEntrance_1200x675

The US FDA decided not to adjust the FY 2019 GDUFA program fee to account for firms that could jump tiers in the middle of the fiscal year, potentially saving ANDA owners some money.

FDA also changed a variable that was used in its calculations, another example of FDA learning how to use its...

Welcome to Pink Sheet

Create an account to read this article

More from US FDA

New US FDA AI Councils Will Focus On Internal, External Policy

 

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

US FDA Leadership Changes Become Reality TV

 

Suddenly the leadership changes at the US FDA’s Center for Biologics Evaluation & Research have begun to feel like a soap opera. That is not a recipe for regulatory predictability.

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.

Precigen’s Papzimeous Approval Allows US FDA CBER Director To Emphasize Flexibility

 

Returning FDA biologics center director Vinay Prasad used the Papzimeous approval announcement to reinforce his flexibility on rare disease therapies after several complete response letters and his brief departure from the agency.

More from Agency Leadership

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.

Boosting EU Clinical Trials: EMA Opens Dialogue With Global CRO Group

 
• By 

The European Medicines Agency’s inaugural bilateral meeting with the Association of Clinical Research Organizations underscores ACRO’s commitment to advancing innovation and its presence in the EU clinical trials ecosystem.

Precigen’s Papzimeous Approval Allows US FDA CBER Director To Emphasize Flexibility

 

Returning FDA biologics center director Vinay Prasad used the Papzimeous approval announcement to reinforce his flexibility on rare disease therapies after several complete response letters and his brief departure from the agency.